GSK Consumer Tries On Wearable Pain Relief With NeuroMetrix Deal
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
GSK Consumer purchases ex-US rights to pain relief device Quell from NeuroMetrix in a deal that includes co-development of transcutaneous electrical nerve stimulation products.
You may also be interested in...
NeuroMetrix Rceives GSK 'Bridge' For Quell Wearable Pain-Relief Development
Recent modifications accelerated portion of milestones remaining in firms' agreement over the next 12 months, reduced GSK's aggregate amount payable and forwarded $2m to NeuroMetrix. Firms are co-funding future development of Quell technology and additional TENS products for chronic pain beginning in 2019.
Smartphone Apps Appropriate For OTC Product Instructions – Consultant
“The present has passed us by” in using appropriate technology to provide consumers more information than on US Drug Facts labels, Pinney Associates’ Saul Shiffman says at CPHA conference.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.